vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 32.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 40.7%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
CLMB vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $129.7M |
| Net Profit | $3.3M | — |
| Gross Margin | 14.5% | 98.0% |
| Operating Margin | 2.1% | -25.0% |
| Net Margin | 1.8% | — |
| Revenue YoY | 32.1% | 73.4% |
| Net Profit YoY | -9.5% | — |
| EPS (diluted) | $0.18 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $129.7M | ||
| Q3 25 | $161.3M | $164.9M | ||
| Q2 25 | $159.3M | $114.4M | ||
| Q1 25 | $138.0M | $81.7M | ||
| Q4 24 | $161.8M | $74.8M | ||
| Q3 24 | $119.3M | $62.9M | ||
| Q2 24 | $92.1M | $54.1M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $4.7M | $25.7M | ||
| Q2 25 | $6.0M | $-12.8M | ||
| Q1 25 | $3.7M | $-41.2M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $5.5M | $-54.8M | ||
| Q2 24 | $3.4M | $-70.4M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 98.0% | ||
| Q3 25 | 15.9% | 99.0% | ||
| Q2 25 | 16.5% | 98.7% | ||
| Q1 25 | 16.9% | 94.3% | ||
| Q4 24 | 19.3% | 96.6% | ||
| Q3 24 | 20.3% | 97.4% | ||
| Q2 24 | 20.2% | 96.2% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | -25.0% | ||
| Q3 25 | 4.3% | 15.1% | ||
| Q2 25 | 5.0% | -11.1% | ||
| Q1 25 | 3.5% | -52.2% | ||
| Q4 24 | 7.2% | -81.2% | ||
| Q3 24 | 7.1% | -89.3% | ||
| Q2 24 | 4.6% | -125.1% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.9% | 15.6% | ||
| Q2 25 | 3.7% | -11.1% | ||
| Q1 25 | 2.7% | -50.4% | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.6% | -87.1% | ||
| Q2 24 | 3.7% | -130.1% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.04 | ||
| Q3 25 | $1.02 | $0.28 | ||
| Q2 25 | $1.30 | $-0.14 | ||
| Q1 25 | $0.81 | $-0.47 | ||
| Q4 24 | $1.52 | $-0.71 | ||
| Q3 24 | $1.19 | $-0.70 | ||
| Q2 24 | $0.75 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $114.8M |
| Total Assets | $458.8M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $93.0M | ||
| Q3 25 | $49.8M | $110.9M | ||
| Q2 25 | $28.6M | $75.2M | ||
| Q1 25 | $32.5M | $61.9M | ||
| Q4 24 | $29.8M | $58.5M | ||
| Q3 24 | $22.1M | $36.4M | ||
| Q2 24 | $48.4M | $32.3M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $114.8M | ||
| Q3 25 | $109.3M | $73.6M | ||
| Q2 25 | $105.2M | $32.7M | ||
| Q1 25 | $95.6M | $32.8M | ||
| Q4 24 | $90.6M | $59.1M | ||
| Q3 24 | $87.7M | $-30.5M | ||
| Q2 24 | $79.8M | $15.1M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $605.2M | ||
| Q3 25 | $376.1M | $538.6M | ||
| Q2 25 | $420.7M | $555.3M | ||
| Q1 25 | $370.1M | $548.8M | ||
| Q4 24 | $469.2M | $594.1M | ||
| Q3 24 | $371.9M | $504.4M | ||
| Q2 24 | $302.8M | $551.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $60.7M | ||
| Q3 25 | $22.2M | $14.3M | ||
| Q2 25 | $-2.2M | $5.0M | ||
| Q1 25 | $8.5M | $-42.2M | ||
| Q4 24 | $16.0M | $-35.7M | ||
| Q3 24 | $-3.6M | $-42.5M | ||
| Q2 24 | $7.3M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | 0.56× | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
